Skip to content

Author

Paulina N. Esguerra

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract A036: Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with an unmet need for novel precision based therapies. While KRAS canonically drives tumor progression, MYC amplification has emerged as a critical downstream resistance mechanism. Efforts have been made to elucidate the role of MYC amplification in PDAC...

Audrey G. Sawyer, Lauryn E. Flannagan, Paulina N. Esguerra et al. · 0 citations
Sep 2026

Abstract B127: Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality and comprises molecular subtypes characterized by MYC amplification (14%) or MYC overexpression (40%), both of which drive tumor proliferation, metabolic reprogramming, and cellular plasticity. MYC dysregulation is associated w...

Paulina N. Esguerra, Michela Cadarso, Sasha Livingwell et al. · 0 citations
Sep 2026

Abstract B043: Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer related mortality with a critical need for novel therapeutic strategies. Cyclin dependent kinase 9 (CDK9) is a transcriptional regulator of RNA polymerase II (Pol II) by phosphorylation of serine residues on the C terminal domain of the pos...

Michela Cadarso, Paulina N. Esguerra, Lauryn E. Flannagan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.